Johnson & Johnson (NYSE:JNJ) Shares Purchased by Traveka Wealth LLC

Traveka Wealth LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 216.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,367 shares of the company’s stock after purchasing an additional 4,353 shares during the quarter. Traveka Wealth LLC’s holdings in Johnson & Johnson were worth $921,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. BCS Wealth Management acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $560,000. First Financial Corp IN increased its stake in shares of Johnson & Johnson by 15.0% during the 4th quarter. First Financial Corp IN now owns 3,135 shares of the company’s stock valued at $453,000 after acquiring an additional 408 shares during the last quarter. Signet Financial Management LLC increased its stake in shares of Johnson & Johnson by 11.0% during the 4th quarter. Signet Financial Management LLC now owns 17,940 shares of the company’s stock valued at $2,594,000 after acquiring an additional 1,775 shares during the last quarter. PFW Advisors LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $2,093,000. Finally, Catalyst Private Wealth LLC increased its stake in shares of Johnson & Johnson by 6.3% during the 4th quarter. Catalyst Private Wealth LLC now owns 2,045 shares of the company’s stock valued at $296,000 after acquiring an additional 121 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JNJ shares. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 7th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Bank of America reiterated a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Stock Up 0.1 %

NYSE JNJ opened at $144.68 on Wednesday. The stock has a market cap of $348.33 billion, a PE ratio of 20.94, a P/E/G ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The business has a 50 day moving average price of $149.12 and a two-hundred day moving average price of $156.09. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.66 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.